Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?

Nature Clinical Practice Gastroenterology & Hepatology volume 2, pages 20–21 (2005)Cite this article

boxed-textCunningham D et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345

Cetuximab and irinotecan combination therapy should be considered for patients with CRC because it leads to greater response rates than cetuximab monotherapy

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Herbst RS and Shin DM (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94: 1593–1611

    Article  CAS  Google Scholar 

  2. Saltz L et al. (2001) Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) (abstr 7). Proc Am Soc Clin Oncol 20: 3a

    Google Scholar 

  3. Saltz L et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201–1208

    Article  CAS  Google Scholar 

  4. Ellis LM and Hoff PM (2004) Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer. J Clin Oncol 22: 1177–1179

    Article  Google Scholar 

  5. Tabernero JM et al. (2004) An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results (abstr 3512). Proc Am Soc Clin Oncol 23: 248

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Minal Chande, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. an Oncologist at the Medical Oncology Unit, San Carlo Hospital, Potenza, Italy

    Gerardo Rosati

Authors
  1. Gerardo Rosati
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerardo Rosati.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosati, G. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?. Nat Rev Gastroenterol Hepatol 2, 20–21 (2005). https://doi.org/10.1038/ncpgasthep0066

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0066

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing